Effect of ezetimibe/simvastatin (EZE/SIM) versus SIM monotherapy on the lipid profile of hypercholesterolemic (HC) patients with metabolic syndrome (MetS)

被引：0
|
作者：
Feldman, T
Zakson-Aiken, M
Shah, A
MacCubbin, D
Tribble, D
Veltri, E
Michel, Y
机构：
来源：
DIABETES | 2005年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A148 / A148
页数：1
相关论文
共 46 条
  • [21] Effect of demographic and baseline lipid/metabolic factors on the efficacy of ezetimibe/simvastatin (E/S) and atorvastatin (A) therapies in type 2 diabetes (T2DM) patients with hypercholesterolemia (HC)
    Goldberg, Ronald B.
    Guyton, John R.
    Mazzone, Theodore
    Weinstock, Ruth S.
    Polis, Adam
    Tomas, Joanne E.
    Tershakovec, Andrew M.
    DIABETES, 2008, 57 : A250 - A251
  • [22] Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial
    Bach, Richard G.
    Cannon, Christopher P.
    Giugliano, Robert P.
    White, Jennifer A.
    Lokhnygina, Yuliya
    Bohula, Erin A.
    Califf, Robert M.
    Braunwald, Eugene
    Blazing, Michael A.
    JAMA CARDIOLOGY, 2019, 4 (09) : 846 - 854
  • [23] Achievement of specified lipid and hs-CRP levels with ezetimibe/simvastatin vs atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease
    Rosen, J.
    Robinson, J.
    Parving, H. -H.
    Ballantyne, C.
    Grundy, S.
    Hsueh, W.
    Lin, J.
    Shah, A.
    Hanson, M. E.
    Teshakovec, A. M.
    DIABETOLOGIA, 2010, 53
  • [24] Effect of ezetimibe/simvastatin (E/S) versus atorvasiatin (A) on lipoprotein subclasses in type 2 diabetes (T2DM) patients with hypercholesterolemia (HC)
    Mazzone, Theodore
    Goldberg, Ronald B.
    Guyton, John R.
    Weinstock, Ruth S.
    Polis, Adam
    Tomassini, Joanne E.
    Tershakovec, Andrew M.
    DIABETES, 2008, 57 : A251 - A252
  • [25] EFFECT OF A FIXED-DOSE COMBINATION OF PITAVASTATIN AND EZETIMIBE, VERSUS MONOTHERAPY ON LIPID PROFILES IN PATIENTS WITH HYPERCHOLESTEROLEMIA: A MULTICENTER, PHASE III STUDY
    Chou, M. -T.
    ATHEROSCLEROSIS, 2023, 379
  • [26] EFFECT OF AGE/GENDER/RACE ON EZETIMIBE/SIMVASTATIN VS. ATORVASTATIN EFFICACY IN METABOLIC SYNDROME PATIENTS WITH MODERATELY HIGH/HIGH CHD RISK
    Robinson, J.
    Ballantyne, C.
    Grundy, S.
    Hsueh, W.
    Parving, H.
    Rosen, J.
    Lin, J.
    Lowe, R.
    Shah, A.
    Tershakovec, A.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [27] EFFECT OF COMBINATION THERAPY OF FLUVASTATIN/FENOFIBRATE VERSUS SIMVASTATIN/EZETROL ON LDL-SUBFRACTIONS IN PATIENTS WITH METABOLIC SYNDROME
    Winkler, K.
    Wunderlich, T.
    Oeduenc, N.
    Schaefer, G.
    Siegel, E.
    Abletshauser, C.
    ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (01) : 192 - 192
  • [28] The short-term effect of atorvastatin plus ezetimibe therapy versus atorvastatin monotherapy on clinical outcome in acute coronary syndrome patients by gender
    Japaridze, Lasha
    Sadunishvili, Maia
    KARDIOLOGIA POLSKA, 2017, 75 (08) : 770 - 778
  • [29] Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease
    Le, Ngoc-Anh
    Tomassini, Joanne E.
    Tershakovec, Andrew M.
    Neff, David R.
    Wilson, Peter W. F.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2015, 4 (10):
  • [30] Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome
    Agouridis, A. P.
    Kostapanos, M. S.
    Tsimihodimos, V.
    Kostara, C.
    Mikhailidis, D. P.
    Bairaktari, E. T.
    Tselepis, A. D.
    Elisaf, M. S.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2012, 66 (09) : 843 - 853
12345